Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA).

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

With an abundance of therapeutic options for managing diabetic macular edema (DME), what patient characteristics inform your treatment decisions? Does the number of loading doses influence long-term macular fluid outcomes? How are you managing insurance-mandated step-therapy in your patients? In today's episode, host Dr. Jay Sridhar invites Drs. Durga Borkar and Carl Danzig to share how they've integrated new anti-VEGF therapies into clinical practice.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Is the Merit-based Incentive Payment System (MIPS) fulfilling its intended purpose, or is it just causing headaches? Dr. George Williams and Joe Reyes join host Dr. Andrew Pouw to share their expertise and experience with MIPS, including its evolution from prior medical cost control policies and how ophthalmologists can use the IRIS Registry to meet reporting requirements.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts

Drs. Durga Borkar and Katherine Talcott join host Dr. Jay Sridhar to brainstorm ideas for how to maintain and improve the current scientific peer review process in ophthalmology.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts

Drs. Eric Suhler and Nick Butler join host Dr. Ben Young to discuss an old treatment for cystoid macular edema (CME) that may be new to many of us: interferon alpha. They review its use, side effects, and success thus far.

Relevant papers discussed in this episode:

• Treatment of refractory cystoid macular edema with pegylated interferon alfa-2A: a retrospective chart review
• Interferon alpha 2b in the treatment of uveitic cystoid macular edema

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts

Dr. Scott Goldstein joins host Dr. Amanda Redfern to share his approach to managing nasolacrimal duct obstruction (NLDO) in kids and his 3-step test for evaluating epiphora in adults, including how to identify complicating factors that may warrant surgical or procedural intervention.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

In today's episode, host Dr. Ben Young welcomes 3 core members of the Academy's Advocacy team: Dr. John McAllister, Secretary for Federal Affairs; Dr. John Peters, Secretary for State Affairs; and Rebecca Hyder, Vice President of Government Affairs. The panel discusses why routine patient care and advocacy go hand in hand, and how ophthalmologists can be better advocates for our patients at the clinic, local, state, and federal level.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Host Dr. Andrew Pouw welcomes Drs. Gustavo De Moraes, Aakriti Shukla, and Simon John to discuss their team's work spanning the full arc of nicotinamide as a neuroprotection candidate for glaucoma, from bench to clinical trials.

For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.